









Markets
/
Stocks
/
nasdaq-cocp
/

Cocrystal Pharma Inc

COCP

0.970USD

+0.110+12.75%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

12.65MMarket Cap

LossP/E TTM



Cocrystal Pharma Inc

0.970

+0.110+12.75%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cocrystal Pharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cocrystal Pharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 113 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cocrystal Pharma Inc's Score

Industry at a Glance

Industry Ranking

113 / 392

Overall Ranking

246 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cocrystal Pharma Inc Highlights

StrengthsRisks

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses (HCV). It is developing small molecule antiviral therapeutics that inhibit the essential viral replication function of RNA viruses, causing acute and chronic viral diseases. It has several candidates under development for the treatment of influenza infection. CC-42344 is a novel PB2 inhibitor, which is a preclinical lead for the treatment of pandemic and seasonal influenza A. It also develops broad-spectrum influenza antivirals targeting replication enzymes of influenza A and B strains. Its broad-spectrum antiviral drug candidate, CDI-988, is an oral treatment for SARS-CoV-2, the virus that causes COVID-19. Its CC-31244, an HCV NNI, is a pan-genotypic inhibitor of NS5B polymerase for the treatment of HCV.

Fairly Valued

The company’s latest PE is -1.04, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 127.93K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 1.07.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

8.000

Target Price

+830.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cocrystal Pharma Inc is 6.87, ranking 194 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.87

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.66

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cocrystal Pharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cocrystal Pharma Inc is 7.96, ranking 71 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.04, which is -104.41% below the recent high of 0.05 and -70.67% above the recent low of -1.77.

Score

Industry at a Glance

Previous score

7.96

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 113/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cocrystal Pharma Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 10.00 and a low of 6.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 2 analysts

Buy

Current Rating

8.000

Target Price

+733.33%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Cocrystal Pharma Inc

COCP

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cocrystal Pharma Inc is 6.71, ranking 185 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.17 and the support level at 0.81, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.18

Change

0.53

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.029

Sell

RSI(14)

44.752

Neutral

STOCH(KDJ)(9,3,3)

32.219

Buy

ATR(14)

0.064

Low Volatility

CCI(14)

-104.244

Sell

Williams %R

55.772

Sell

TRIX(12,20)

-0.344

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

0.946

Buy

MA10

0.978

Sell

MA20

1.035

Sell

MA50

1.025

Sell

MA100

1.078

Sell

MA200

1.325

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cocrystal Pharma Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 5.13%, representing a quarter-over-quarter decrease of 5.40%. The largest institutional shareholder is The Vanguard, holding a total of 263.99K shares, representing 1.92% of shares outstanding, with 29.32% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Frost Gamma Investments Trust

1.71M

+1.18%

Hassan (Fred)

1.38M

+35.29%

Schinazi (Raymond F)

637.06K

Wilcox (Sue)

564.95K

The Vanguard Group, Inc.

Star Investors

268.08K

Renaissance Technologies LLC

Star Investors

127.93K

+2.32%

Geode Capital Management, L.L.C.

73.93K

+1.13%

BlackRock Institutional Trust Company, N.A.

73.75K

Lee (Sam Ph.D.)

56.35K

Kornberg (Roger D)

53.82K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cocrystal Pharma Inc is 3.04, ranking 175 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.22. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.